<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">INOMO, TOSHIAKI</style></author><author><style face="normal" font="default" size="100%">OHNO, MASASUKE</style></author><author><style face="normal" font="default" size="100%">NAGASAKA, TORU</style></author><author><style face="normal" font="default" size="100%">KURAMITSU, SHUNICHIRO</style></author><author><style face="normal" font="default" size="100%">ITO, EIJI</style></author><author><style face="normal" font="default" size="100%">WATANABE, TADASHI</style></author><author><style face="normal" font="default" size="100%">FUJITA, MITSUGU</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterization of Tumor Immune Microenvironment in Meningiomas: Correlation of Tumor-infiltrating Lymphocyte Aggregates With Tumor Grade</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3487-3496</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.17710</style></doi><volume><style face="normal" font="default" size="100%">45</style></volume><issue><style face="normal" font="default" size="100%">8</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Malignant meningiomas are aggressive intracranial tumors with high recurrence rates and limited treatment options. The tumor immune microenvironment (TIME) plays a pivotal role in the tumor progression and treatment response. However, its role in meningioma remains largely unknown. This study aimed to analyze tumor-infiltrating lymphocytes (TILs) within the meningioma TIME and investigate their correlation with clinical parameters.Patients and Methods: Using tumor specimens from patients diagnosed with meningioma (grade 1, 12 cases; grade 2, 10 cases), the densities of CD4+ T-cells, CD8+ T-cells, CD20+ B-cells, and tissue-resident memory T-cells were quantified using multicolor immunohistochemistry and the QuPath software. The results were analyzed along with clinical parameters, including tumor grades.Results: The density of individual TIL subsets did not correlate with the tumor grades or patients’ postoperative neurological function. TIL aggregates were observed in grade 2 meningiomas; clusters of abundant B-cells with a few follicular helper T-cells were observed in one case, indicating the presence of immature tertiary lymphoid structures. A positive correlation was observed between the densities of CD4+ and CD8+ T-cells in grade 2 meningiomas but not in grade 1.Conclusion: The TIME in meningiomas exhibits distinct immune profiles by tumor grade, characterized by the presence of TIL aggregates and coordinated CD4+ and CD8+ T-cell infiltration in higher-grade tumors. These findings may provide insights into the immune landscape of meningiomas and support the development of immunotherapeutic strategies targeting the TIME.</style></abstract></record></records></xml>